Case report : Development of anxiety symptoms after receiving the Pfizer-BioNTech (BNT162b2) COVID-19 vaccine: a case series

Simple item page
dc.contributor.authorTaube, Māris
dc.contributor.authorLesiņa, Alise Alma
dc.contributor.institutionDepartment of Psychosomatic Medicine and Psychotherapy
dc.date.accessioned2025-01-27T10:25:01Z
dc.date.available2025-01-27T10:25:01Z
dc.date.issued2024
dc.descriptionPublisher Copyright: Copyright © 2025 Taube and Lesiņa.
dc.description.abstractSevere acute respiratory sindrome - Coronavirus - 2 (SARS-CoV-2) (Coronavirus disease - 19 (COVID-19)) infection can result in long-term health consequences, such as long COVID. The clinical manifestations of long COVID include depression, anxiety, brain fog with cognitive dysfunction, memory issues, and fatigue. However, the links between vaccination and psychiatric disorders have been less studied. This article describes three patients who reported anxiety after receiving a complete course of the Pfizer-BioNTech BNT162b2 vaccine. It is important to explore the relationship between anxiety, other mental health disorders, and COVID-19 vaccination, as well as to investigate potential pathogenetic mechanisms.en
dc.description.statusPeer reviewed
dc.format.extent292064
dc.identifier.citationTaube, M & Lesiņa, A A 2024, 'Case report : Development of anxiety symptoms after receiving the Pfizer-BioNTech (BNT162b2) COVID-19 vaccine: a case series', Frontiers in Psychiatry, vol. 15, 1514428. https://doi.org/10.3389/fpsyt.2024.1514428
dc.identifier.doi10.3389/fpsyt.2024.1514428
dc.identifier.issn1664-0640
dc.identifier.otherMendeley: 27df56ae-8ce1-366f-b271-2cd66feccc3b
dc.identifier.otherunpaywall: 10.3389/fpsyt.2024.1514428
dc.identifier.urihttps://dspace.rsu.lv/jspui/handle/123456789/17039
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85216742691&partnerID=8YFLogxK
dc.language.isoeng
dc.relation.ispartofFrontiers in Psychiatry
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectCOVID-19 vaccines
dc.subjectSARS-CoV-2 vaccine
dc.subjectBioNTech162 vaccine
dc.subjectanxiety
dc.subjectcase reports
dc.subject3.3 Health sciences
dc.subject3.5 Other medical sciences
dc.subject3.2 Clinical medicine
dc.subject1.1. Scientific article indexed in Web of Science and/or Scopus database
dc.subjectSDG 3 - Good Health and Well-being
dc.titleCase report : Development of anxiety symptoms after receiving the Pfizer-BioNTech (BNT162b2) COVID-19 vaccine: a case seriesen
dc.type/dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Development_of_anxiety.pdf
Size:
285.22 KB
Format:
Adobe Portable Document Format
Download

Collections

Research outputs from Pure / Zinātniskās darbības rezultāti no ZDIS Pure